New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.71 0.14 +0.51%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Pfizer Inc. (PFE) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 30, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits Officer departure
10-Q Sep 27, 2026 P1I2: 14 added · 11 removed · 67 modified
P2I1A: no comparison — incorporated by reference
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 28, 2026 P1I2: 37 added · 7 removed · 50 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 18, 2026 7.01 Regulation FD disclosure
8-K Jun 18, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Mar 29, 2026 P1I2: 18 added · 63 removed · 69 modified
P2I1A: no comparison — incorporated by reference
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 23, 2026 5.07 Submission of matters to a vote of security holders
10-K Dec 31, 2025 1: 35 added · 24 removed · 77 modified
1A: 8 added · 2 removed · 48 modified
7: 39 added · 50 removed · 71 modified
8-K Feb 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 16, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 13, 2025 8.01 Other events
10-Q Sep 28, 2025 P1I2: 24 added · 15 removed · 64 modified
P2I1A: no comparison — incorporated by reference
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 29, 2025 P1I2: 19 added · 12 removed · 67 modified
P2I1A: no comparison — incorporated by reference
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 30, 2025 P1I2: no comparison — the earlier filing's text is no longer kept
P2I1A: no comparison — incorporated by reference
8-K Apr 29, 2025 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 29, 2024
8-K Oct 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 14, 2023 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.